Lipid injectable emulsions: 2006

Nutrition in Clinical Practice

Volumn 21, Issue 4, 2006, Pages 381-386

  Driscoll, David F ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; LIPID EMULSION; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TRIACYLGLYCEROL;

ANIMAL; CHEMISTRY; DRUG STABILITY; HUMAN; INJECTION; MEDICAL LITERATURE; METABOLISM; PARENTERAL NUTRITION; PARTICLE SIZE; PH; REVIEW; SAFETY; STANDARD;

ANIMALS; DRUG STABILITY; FAT EMULSIONS, INTRAVENOUS; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS; PARENTERAL NUTRITION; PARTICLE SIZE; PHARMACOPOEIAS; SAFETY; TRIGLYCERIDES;

EID: 34548143146     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426506021004381     Document Type: Review

References (40)

1. Geyer R. Parenteral nutrition. Physiol Rev. 1960;40:150-186.
2. Wretlind A. Development of fat emulsions. JPEN J Parenler Enteral Nutr. 1981;5:230-235.
3. Driscoll DF, Bistrian BR. Clinical issues in the therapeutic monitoring of total parenteral nutrition. Clin Lab Med. 1987;7: 699-714.
4. Driscoll DF. Examination of selection of light-scattering and light-obscuration acceptance criteria for lipid injectable emulsions. Pharm Forum. 2004;30:2244-2253.
5. Driscoll DF. Intravenous lipid emulsions. Nutr Clin Pract. 2001; 2001:215-218.
6. Chapter 729. Globule size distribution in lipid injectable emulsions. Pharm Forum. 2005;31:1448-1453.
7. Lipid injectable emulsions: in-process revision. Pharm Forum. 2006;32:350-353.
8. Bistrian BR. Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads lecture. JPEN J Parenter Enteral Nutr. 2003; 27:168-175.
9. Mascioli EA, Babayan VK, Bistrian BR, Blackburn GL. Novel triglycerides for special medical purposes. JPEN J Parenter Enteral Nutr. 1988;12(6 Suppl):127S-132S.
10. The British Nutrition Foundation. Unsaturated Fatty Acids: Nutritional and Physiological Significance. London: Chapman & Hall; 1992.
11. Carpentier YA, Van Gossum A, Dubois DY, Deckelbaum RJ. Lipid metabolism in parenteral nutrition. In: Rombeau JL, Caldwell MD, eds. Clinical Nutrition: Parenteral Nutrition. Philadelphia, PA: VV.B. Saunders; 1993:35-74.
12. Chapter 797. Pharmaceutical Compounding: Sterile Preparations: Physical Tests: United States Pharmacopeia 29/National Formulary 24. Rockville, MD: United States Pharmacopeia Convention, Inc; 2006:2735-2751.
13. Driscoll DF, Silvestri AP, Nehne J, Klutsch K, Bistrian BR, Niemann W. Physicochemical stability of highly concentrated total nutrient admixtures for fluid-restricted patients. Am J Health Syst Pharm. 2006;63:79-85.
14. Driscoll DF, Bistrian BR. The effects of packaging containers on the large-diameter tail of the globule size distribution (GSD) of lipid emulsions [abstract]. Clin Nutr. 2005;24:699.
15. Driscoll DF, Silvestri AP, Bistrian BR, Mikrut BA. All-in-one (AIO) stability differences with lipids packaged in glass vs. plastic [abstract]. Clin Nutr. 2005;24:700.
16. Driscoll DF, Thoma A, Klutsch K, Bistrian BR, Nehne J. The effects of packaging and manufacturer on the large-diameter tail of the globule size distribution of lipid injectable emulsions: part 2 [abstract]. Clin Nutr. 2005;24:1126-1127.
17. Driscoll DF, Bhargava HN, Zaim RH, Babayan VK, Bistrian BR. Physicochemical stability of total nutrient admixtures. Am J Health Syst Pharm. 1995;52:623-634.
18. Coronado MP, William B, Gibson D. Total nutrient admixture instability associated with high amino acid concentration [abstract]. Nutr Clin Pract. 2004;19:96. Abstract N071.
19. Driscoll DF, Giampietro K, Wichelhaus DP, et al. Physicochemical stability assessments of lipid emulsions of varying oil composition. Clin Nutr. 2001;20:151-157.
20. Driscoll DF, Bacon MN, Bistrian BR. Physicochemical stability of two different types of intravenous lipid emulsion as total nutrient admixtures. JPEN J Parenter Enteral Nutr. 2000;24:15-22.
21. Driscoll DF, Nehne J, Peterss H, Franke R, Bistrian BR, Niemann \V. The influence of medium-chain triglycerides on the stability of all-in-one formulations. Int J Pharm. 2002;240:1-10.
22. Driscoll DF, Nehne J, Peterss H, Klutsch K, Bistrian BR, Niemann W. Physicochemical stability of intravenous lipid emulsions as all-in-one admixtures intended for the very young. Clin Nutr. 2003;22:489-495.
23. Sacks GS, Driscoll DF. Does lipid hang time make a difference? Time is of the essence. Nutr Clin Pract. 2002;17:284-290.
24. Holman RT, Johnson SB, Hatch TF. A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr. 1982;35:617-623.
25. th ed. Baltimore, MD: Lippincott, Williams & Wilkins; 2006.
26. Klein S, Miles JM. Metabolic effects of long-chain and medium-chain triglycerides in humans. JPEN J Parenter Enteral Nutr. 1994;18:396-397.
27. Driscoll DF, Etzler F, Barber TA, Nehne J, Niemann W, Bistrian BR. Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction. Int J Pharm. 2001;219: 21-37.
28. Driscoll DF. Physicochemical assessment of total nutrient admixture stability and safety: quantifying the risk [editorial]. Nutrition. 1997;12:166-167.
29. Driscoll DF. The significance of particle-sizing measurements in the safe use of intravenous fat emulsions. J Disp Sci Tech. 2002;23:679-687.
30. Driscoll DF, Ling PR, Quist WC, Bistrian BR. Pathological consequences from the infusion of unstable lipid emulsion admixtures in guinea pigs. Clin Nutr. 2005;24:105-113.
31. Driscoll DF, Ling PR, Quist WC, Bistrian BR. Hepatic indicators of inflammation following the infusion of pharmaceutically unstable all-in-one mixtures in rats. Clin Nutr. 2003;22:S16-S17,0-59.
32. Driscoll DF, Ling PR, Bistrian BR. Hepatic indicators of oxidative stress following a 72-h infusion of an unstable all-in-one (AIO) in rats. Clin Nutr. 2004;23:857.
33. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2002;23:759-769.
34. Reiter PD. Sterility of intravenous fat emulsion in plastic syringes. Am J Health Syst Pharm. 2002;59:1857-1859.
35. rd ed. Philadelphia, PA: W. B. Saunders and Co; 2001:35-59.
36. Hasselmann M, Reimund JM. Lipids in the nutritional support of critically ill patients. Curr Opin Crit Care. 2004;10:449-455.
37. Lekka ME, Liokatis S, Nathanail C, Galani V, Nakos G. The impact of intravenous fat emulsion administration in acute lung injury. Am Rev Respir Crit Care Med. 2004;169:638-644.
38. McCowen KC, Bistrian BR. Essential fatty acids and their derivatives. Curr Opin Gastroenterol. 2005;21:207-215.
39. Alwayn IP, Gura K, Nose V, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic liver disease. Pediatr Res. 2005;57:445-452.
40. Gura KM, Duggan C, Collier S, et al. Reversal of parenteral nutrition associated liver disease in two infants using parenteral fish oil. Pediatrics. 2006. In press.